April 18, 2024Open Access

Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The role of immune checkpoint inhibitors (ICI) expands but affordable and reproducible prognostic biomarkers are needed. We investigated the association between baseline and 3-month absolute lymphocyte count (ALC) and survival for patients on ICI.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Conroy et al. (Thu,) studied this question.

synapsesocial.com/papers/68e6e8a8b6db6435876637e5 https://doi.org/https://doi.org/10.1038/s44276-024-00058-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The effect of radiation therapy on lymphocyte subpopulations in cancer patients1976 · 108 citations
2Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%2021 · 1,111 citations
3DNA mismatch repair in cancer2018 · 576 citations
4Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab2009 · 61 citations
5An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access2021 · 171 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo